# ImmunoACT

Source: https://onco.cc/companies/immunoact/  
OnCo record `immunoact` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.

## Summary

ImmunoACT was established in 2018 as a spin-off from IIT Bombay, where Rahul Purwar's group had worked on a humanised CD19 CAR since 2013. Clinical development ran with Tata Memorial Centre: first patients were dosed at Tata Memorial Hospital in 2021 and the DCGI granted market authorisation for NexCAR19 (talicabtagene autoleucel) in 2023, India's first approved CAR-T therapy. The phase 1/2 study (64 enrolled at six centres) reported an overall response rate of 73% in 51 evaluable patients. The company reports more than 600 patients treated across over 130 authorised centres, a 98% manufacturing success rate, about 20 days from apheresis to infusion and a WHO-certified GMP facility with capacity for 750 patients a year, expanding to 1,500. It received a US patent in 2025 and in 2026 partnered with Cipla to supply South Africa, Algeria and Morocco.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Mumbai
- Type: cell-therapy
- Website: https://immunoact.com

## Sources

- Official website: https://immunoact.com
- Phase 1/2 results (Lancet Haematol 2025): https://doi.org/10.1016/S2352-3026(24)00377-6

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/)
- companies: [Cipla](https://onco.cc/companies/cipla/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [Department of Biotechnology, Government of India](https://onco.cc/institutions/dbt-india/), [Indian Institute of Technology Bombay](https://onco.cc/institutions/iit-bombay/), [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- people: [Gaurav Narula](https://onco.cc/people/narula-gaurav/), [Hasmukh Jain](https://onco.cc/people/jain-hasmukh/), [Rahul Purwar](https://onco.cc/people/purwar-rahul/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- trials: [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/)
- key papers: [Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study](https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/immunoact.json